These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38863863)

  • 1. Comparison of Efficacy and Pharmacoeconomic Outcomes Between Calfactant and Poractant Alfa in Preterm Infants With Respiratory Distress Syndrome.
    Bui A; Schumann C; Le J; Jones T; Schwendeman C
    J Pediatr Pharmacol Ther; 2024 Jun; 29(3):241-247. PubMed ID: 38863863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness of surfactant preparations in premature infants.
    Trembath A; Hornik CP; Clark R; Smith PB; Daniels J; Laughon M;
    J Pediatr; 2013 Oct; 163(4):955-60.e1. PubMed ID: 23769501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of surfactant-TA, calfactant and poractant alfa for preterm infants with respiratory distress syndrome: a retrospective study.
    Jeon GW; Oh M; Sin JB
    Yonsei Med J; 2015 Mar; 56(2):433-9. PubMed ID: 25683992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the Pharmacoeconomics of Calfactant and Poractant Alfa in Surfactant Replacement erapy.
    Zayek MM; Eyal FG; Smith RC
    J Pediatr Pharmacol Ther; 2018; 23(2):146-151. PubMed ID: 29720917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy analysis of different pulmonary surfactants in premature infants with respiratory distress syndrome].
    Xu H; Xu P
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2021 Feb; 33(2):174-179. PubMed ID: 33729136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of porcine versus bovine surfactants for preterm newborns with respiratory distress syndrome: systematic review and meta-analysis.
    Singh N; Hawley KL; Viswanathan K
    Pediatrics; 2011 Dec; 128(6):e1588-95. PubMed ID: 22123870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome.
    Sinha SK; Lacaze-Masmonteil T; Valls i Soler A; Wiswell TE; Gadzinowski J; Hajdu J; Bernstein G; Sanchez-Luna M; Segal R; Schaber CJ; Massaro J; d'Agostino R;
    Pediatrics; 2005 Apr; 115(4):1030-8. PubMed ID: 15805381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, controlled trial of poractant alfa versus beractant in the treatment of preterm infants with respiratory distress syndrome.
    Dizdar EA; Sari FN; Aydemir C; Oguz SS; Erdeve O; Uras N; Dilmen U
    Am J Perinatol; 2012 Feb; 29(2):95-100. PubMed ID: 22105435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of two different early rescue surfactant treatments on mortality in preterm infants with respiratory distress syndrome.
    Kadıoğlu Şimşek G; Kanmaz Kutman HG; Canpolat FE; Oğuz ŞS
    Clin Respir J; 2020 Mar; 14(3):285-290. PubMed ID: 31814293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The short-term outcome of a large cohort of very preterm infants treated with poractant alfa (Curosurf) for respiratory distress syndrome. A postmarketing phase IV study.
    Lamboley-Gilmert G; Lacaze-Masmonteil T;
    Paediatr Drugs; 2003; 5(9):639-45. PubMed ID: 12956620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health Economic Studies of Surfactant Replacement Therapy in Neonates with Respiratory Distress Syndrome: A Systematic Literature Review.
    Magni T; Ragni C; Pelizzi N; Sharma S; Perez-Kempner L; Turkstra E; Nathani J; Orlovic M; Meshchenkova N
    Pharmacoecon Open; 2023 May; 7(3):359-371. PubMed ID: 36906631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pharmacoeconomic analysis of in-hospital costs resulting from reintubation in preterm infants treated with lucinactant, beractant, or poractant alfa.
    Guardia CG; Moya FR; Sinha S; Simmons PD; Segal R; Greenspan JS
    J Pediatr Pharmacol Ther; 2012 Jul; 17(3):220-7. PubMed ID: 23258964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mortality in preterm infants with respiratory distress syndrome treated with poractant alfa, calfactant or beractant: a retrospective study.
    Ramanathan R; Bhatia JJ; Sekar K; Ernst FR
    J Perinatol; 2013 Feb; 33(2):119-25. PubMed ID: 21886094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose Effect of Poractant Alfa in Neonatal RDS: Analysis of Combined Data from Three Prospective Studies.
    Królak-Olejnik B; Hożejowski R; Szczapa T
    Front Pediatr; 2020; 8():603716. PubMed ID: 33330292
    [No Abstract]   [Full Text] [Related]  

  • 15. Poractant alfa and beractant treatment of very premature infants with respiratory distress syndrome.
    Fujii AM; Patel SM; Allen R; Doros G; Guo CY; Testa S
    J Perinatol; 2010 Oct; 30(10):665-70. PubMed ID: 20336076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health Economics and Outcomes of Surfactant Treatments for Respiratory Distress Syndrome Among Preterm Infants in US Level III/IV Neonatal Intensive Care Units.
    Sekar K; Fuentes D; Krukas-Hampel MR; Ernst FR
    J Pediatr Pharmacol Ther; 2019; 24(2):117-127. PubMed ID: 31019404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants.
    Ramanathan R; Rasmussen MR; Gerstmann DR; Finer N; Sekar K;
    Am J Perinatol; 2004 Apr; 21(3):109-19. PubMed ID: 15085492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poractant alfa versus bovine lipid extract surfactant for infants 24+0 to 31+6 weeks gestational age: A randomized controlled trial.
    Lemyre B; Fusch C; Schmölzer GM; Rouvinez Bouali N; Reddy D; Barrowman N; Huneault-Purney N; Lacaze-Masmonteil T
    PLoS One; 2017; 12(5):e0175922. PubMed ID: 28472058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthetic Surfactant CHF5633 Compared with Poractant Alfa in the Treatment of Neonatal Respiratory Distress Syndrome: A Multicenter, Double-Blind, Randomized, Controlled Clinical Trial.
    Ramanathan R; Biniwale M; Sekar K; Hanna N; Golombek S; Bhatia J; Naylor M; Fabbri L; Varoli G; Santoro D; Del Buono D; Piccinno A; Dammann CE
    J Pediatr; 2020 Oct; 225():90-96.e1. PubMed ID: 32553868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poractant Alfa Versus Beractant for Neonatal Respiratory Distress Syndrome: A Retrospective Cost Analysis.
    Brown S; Hurren J; Sartori H
    J Pediatr Pharmacol Ther; 2018; 23(5):367-371. PubMed ID: 30429690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.